Depomed Rejected Horizon Pharma's Takeout Bid, But Still Trades As If M&A Is Happening

Loading...
Loading...
In a report published Thursday, RBC Capital analyst Randall Stanicky downgraded the rating on
Depomed, Inc.DEPO
from Outperform to Sector Perform, while raising the price target from $26 to $32. While the company reported strong 2Q results and raised its 2015 guidance, Depomed also formally reject the latest unsolicited stock offer from
Horizon Pharma PLCHZNP
. Although the risk/reward appears more balanced now, the stock has risen over 98 percent, year to date. The analyst believes that valuation could be a hurdle for other bidders, limiting upside to the stock. On the other hand, if Depomed continues as a standalone, the analyst believes that there could be downside risk of 25 percent, adding that "the process could be drawn out as DEPO clearly does not appear to be a willing seller in an equity based deal." With NUCYNTA scheduled to be re-launched, it would prove to be key to the value. The management sees "bockbuster" potential in the drug till the end of its patent, with 2020 revenue expected at $500 million. In addition, according to the RBC Capital report, "[T]he company suggested it is actively engaged in discussions to acquire additional products having looked at >60 deals in 1H2015 and that tax inversion opportunities would be on the table."
Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsRBC Capital Markets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...